Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.
Investing.com -- Moderna shares pulled back sharply on Thursday, giving up a small chunk of Wednesday’s record-breaking rally after the stock rocketed as much as 177% on data showing its personalized cancer vaccine, developed with Merck, slowed the spread and recurrence of melanoma. Merck shares had jumped 12.6% on Wednesday alongside Moderna’s surge.
By Mike Dolan Aug 20 (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-at-Large, Finance and Markets Buybacks to the rescue? The surprising move by the U.S.
Moderna (NASDAQ:MRNA) shares fell sharply in premarket trading on Thursday as investors took profits following the biggest one-day rally in the biotechnology company’s history, while concerns over valuation added to the selling pressure. The stock dropped 13.
You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.
Wall Street weighs in on a big day for Moderna.
Moderna and Merck's have been highlighted in this Investment Ideas article.
Moderna, Merck and Target stocks soared to annual highs amid positive company catalysts and strong earnings results.
Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win. mRNA Has ‘Tremendous’ Potential “Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases,” Musk said in a post on X. “Artificial RNA essentially makes curing diseases a software probl
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
The biotech could be on the verge of setting a new standard of care for skin cancer.
Shares of global pharmaceutical company Pfizer (NYSE:PFE) jumped 3.8% in the afternoon session after positive clinical trial results from peers Merck and Moderna for an mRNA cancer treatment lifted sentiment across the pharmaceutical sector.
<body><p>STORY: :: Why Moderna and Merck's cancer vaccine trial may be a milestone</p><p>:: New York / August 19, 2026</p><p>:: Michele Gershberg, Global Health Editor</p><p>"The two drugmakers, Moderna and Merck, gave an overview of a clinical trial that was testing a new cancer vaccine, together with a widely used cancer treatment from Merck called Keytruda. It was testing it in melanoma patients, and, it was a large trial. And they said that what they found is that it works better than just Keytruda by itself, when it comes to preventing the disease from returning, or from spreading to other parts of the body." //</p><p>"The trial itself was looking at patients who had just had their tumors removed surgically. // </p><p>At the moment, Moderna has told us that they expect that there are thousands of patients who could benefit from this if they receive regulatory approval. And that approval, their aim is to get it sometime in 2027." //</p><p>"This is designed to treat melanoma. But there are dozens of studies looking at this and all kinds of cancers. In lung cancer, in pancreatic cancer, colon cancer, a wide array. So this is the first sign, scientifically, that, in a large setting, compared to other kinds of treatment, that this works." //</p><p>"The news is extremely significant for Moderna. Our readers may know Moderna as the maker of a very effective COVID-19 vaccine. And they're, you know, their fortunes surged on that vaccine, you know, during and immediately after the pandemic. But since then, use of the vaccine has slowed. // And the idea of a of a cancer vaccine based on its mRNA technology, has attracted a lot of interest.The news today signals that there is more evidence to think that that hope will materialize, and it will become a big marketplace." //</p><p>"The results are also a real positive for Merck. You know, they are very well known for Keytruda for cancer patients. They are testing this vaccine approach in a number of different trials. So it opens up a new possibility for Merck, and it's, you know, in its own therapy. And that is significant because the patent on that, on Keytruda is expected to expire within or later in this decade. And, you know, and this is, you know, opening up their market for them."</p><p>The companies tested the vaccine together with Merck's immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview.</p><p>This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone. Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers.</p></body>
Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reducing melanoma recurrence and also showed a benefit in preventing the cancer from spreading when used with Merck’s Keytruda. The result is especially important because it is the first positive late-stage trial […]
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector.
1. Moderna shares more than doubled after it reported successful results in an experimental mRNA-based cancer vaccine. The company and its partner Merck reported this morning that the vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients. The positive results sent Moderna’s share price soaring and rippled through drug industry stocks as investors saw the potential for more future blockbusters.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 144% in the afternoon session after its personalized mRNA cancer vaccine, developed with Merck, met key goals in a late-stage trial.
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% a
Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.
One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place and last.